Upstream Bio, Inc. Common Stock

Over 65 pharmaceutical companies are advancing 75+ pipeline COPD drugs, with the treatment landscape evolving beyond traditional bronchodilators toward targeted biologics and anti-inflammatory therapies. Recent clinical trial successes include AstraZeneca's tozorakimab meeting primary endpoints in Phase III trials, and multiple companies progress...

The severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleuki...

Sanofi reported positive Phase 2 data for lunsekimig, its bispecific antibody targeting TSLP and IL-13. The drug met primary endpoints in asthma and nasal polyp studies with significant improvements in exacerbations and polyp size. However, an atopic dermatitis trial missed its primary endpoint, though secondary measures showed some clinical acti...

Upstream Bio announced additional analyses from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP). The drug met its primary endpoint with a nasal polyp score reduction of -1.95 (p < 0.0001) and reduced the need for surgery or systemic corticosteroids by 76% compared to placebo. The company plans to initi...

Upstream Bio announced it will present additional efficacy analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps at the AAAAI Congress 2026. The presentation will include new analyses assessing verekitug's efficacy with adjustment for concomitant rescue therapy use. Verekitug is a novel monoclonal antib...